Abstract
For NSAIDs it has been widely accepted that prostaglandin inhibition is their mechanism of action in clinical use. Yet many other actions have been described, although it is unclear to what extent these may contribute to clinical activity. This review attempts to relate some of the experimental activities of NSAIDs to concentrations of drugs which occur in clinical use. Since it is assumed that to be effective a drug must reach its target site of action, synovial fluid concentrations for NSAIDs are considered. The resulting analysis suggests that prostaglandin inhibition is a viable mode of action for most, if not all, NSAIDs. However, some NSAIDS may rely as much, if not more, on other actions for their anti-inflammatory effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
W. J. Wallis and P. A. Simkin,Antirheumatic drug concentrations in human synovial fluid tissue. Clin. Pharmacokin.8, 496–522 (1983).
H. Spahn, K. Thabe, E. Mutschler, K. Tillmann and I. Gikalov,Concentration of azapropazone in synovial tissues and fluid Eur. J. Clin. Pharmacol.32, 303–307 (1987).
S. Wanwimolruk, P. M. Brooks and D. J. Birkett,Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. Br. J. Clin. Pharmacol.15, 91–94 (1983).
K. Brune, K. D. Rainsford, K. Wagner and B. A. Peskar,Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn-Schmiedeberg's Arch. Pharmacol.315, 269–276 (1981).
S. Rashad, P. Revell, A. Hemingway, F. Low, K. D. Rainsford and F. Walker,Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. The Lancet, 2nd September, 519–522 (1989).
E. Seppala, M. Nissila, H. Isomaki, P, Nuotio, E. Nykanen, O. Laitinen and H. Vapaatalo,Comparison of the effects of different anti-inflammatory drugs of synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin. Rheumatol.4, 315–320 (1985).
D. C. Brater,Drug-drug and drug-disease interactions with non-steroidal anti-inflammatory drugs. Am. J. Med.80, 62–77 (1986).
K. D. Rainsford, A. Davies, L. Mundy and I. Ginsburg,Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in vitro. J. Pharm. Pharmacol.41, 322–330 (1989).
F. Silvieri, A. Allegrezzo Guilietti, S. Muti and G. Piergiacomi,Chemiluminescence of polymorphonuclear leucocytes and non-steroidal anti-inflammatory agents. Clin. Trials. J.25, 390–400 (1988).
P. D. Fowler, M. F. Shadforth, P. R. Crook and V. A. John,Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur. J. Clin. Pharmacol.25, 389–394 (1983).
T. M. Chalmers, R. C. Glass and P. C. Risdall,Concentrations of flurbiprofen in serum and synovial fluid from patients with active rheumatoid disease: some preliminary observations. Curr. Med. Res. Opin.5, 17–20 (1977).
R. C. Glass and A. J. Swannell,Concentrations of ibuprofen in serum and synovial fluid from patients with arthritis. Brit. J. Clin. Pharmacol.6, 453P-454P (1978).
H. W. Emori, G. D. Champion, R. Bluestone and H. E. Paulus,Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann. Rheum. Dis.32, 433–435 (1973).
W. S. Mitchell, P. Scott, A. C. Kennedy, P. M. Brooks, R. Templeton and M. G. Jefferies,Clinico-pharmacological studies on ketoprofen (‘Orudis’). Curr. Med. Res. Opin.3, 423–430 (1975).
S. Jalava, A. Saarimaa, M. Anttila and H. Sundquist,Naproxen concentrations in serum, synovial fluid and synovium. Scand. J. Rheumatol.6, 155–157 (1977).
R. K. Verbeeck, C. J. Richardson and K. L. N. Blocka,Clinical pharmacokinetics of piroxicam. J. Rheumatol.13, 789–796 (1986).
S. H. Dromgoole, D. E. Furst, R. K. Desiraju, R. K. Nayak, M. A. Kirschenbaum and H. E. Paulus,Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clin. Pharmacol. Ther.32, 371–377 (1982).
J. O. Minta and M. D. Williams,Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J. Rheumatol.12, 751–757 (1975).
C. Friman, C. Johnston, C. Chew and P. Davies,Effect of diclofenac sodium, tolfenamic acid and indomethacin on the production of superoxide induced by n-formyl-methionylleucyl-phenylalanine in normal human polymorphonuclear leukocytes. Scand. J. Rheumatol.15, 41–46 (1986).
K. D. Rainsford,Effects of anti-inflammatory drugs on the release from porcine synovial tissue in vitro of interleukin 1 like cartilage degrading activity. Agents and Actions21, 337–340 (1987).
K. G. Couchman and H. Sheppeard,The effect of antirheumatic drugs on factors from porcine synovium inducing chondrocyte mediated cartilage degradation. Agents and Actions19, 116–122 (1986).
D. A. Lewis, R. B. Capstick and R. J. Ancill,The action of azapropazone, oxyphenbutazone and phenylbutazone on lysosomes. J. Pharm. Pharmacol.23, 931–935 (1971).
P. A. Todd and E. M. Sorkin,Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs35, 244–285 (1988).
R. J. Smith, C. Sabin, H. Gilchrest and S. Williams,Effect of anti-inflammatory drugs on lysosomes and lysosomal enzymes from rat liver. Biochem. Pharmacol.25, 2171–2177 (1976).
R. J. Flower and J. R. Vane,Inhibition of prostaglandin biosynthesis. Biochem. Pharmacol.23, 1439–1450 (1974).
J. Migne, Y. Vedrine, G. Bourat, J. Fournel and D. Heusse,Action of ketoprofen on hepatic lysosome in the rat. Rheumatol. Rehabil. Supplement 15–19 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Urquhart, E. A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with theirin vitro activity. Agents and Actions 32, 261–265 (1991). https://doi.org/10.1007/BF01980883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01980883